SUBSCRIBE
SUBSCRIBE
News   Drug Development

ZIOPHARM, Inc. Commences Treatment of First Patients in Two Separate Phase I/II Combination Studies of Both Indibulin and Palifosfamide

February 4, 2008 | 
1 min read

NEW YORK--(BUSINESS WIRE)--ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), announced today that dosing of the first patient took place in two separate new studies, including:

Clinical research Phase I
MORE ON THIS TOPIC
Sanofi's Distribution Center in Quebec, Canada
Multiple sclerosis
Sanofi, Denali Abandon Mid-Stage Multiple Sclerosis Study on Disappointing Data
October 11, 2024
 · 
2 min read
 · 
Tristan Manalac
Drug Development
How AI Could Ease Tension in Clinical Trials
October 10, 2024
 · 
1 min read
 · 
Lori Ellis
Sign in front of Pfizer in Quebec, Canada
Prostate cancer
Pfizer Phase III Prostate Cancer Win Builds Case for Broader Label for Talzenna-Xtandi Combo
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac
Concept art of a gene therapy showing a syringe injecting into a 3D DNA helix
Gene therapy
7 Children Receiving Bluebird’s Gene Therapy Developed Blood Cancers: Study
October 10, 2024
 · 
2 min read
 · 
Tristan Manalac